Ligand Pharmaceuticals Incorpor

LGND

$189.55

Name : Ligand Pharmaceuticals Incorpor

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $3,730,670,080.00

EPSttm : 2.27

Ligand Pharmaceuticals Incorpor

$189.55

3.51%

$6.42

Float Short %

5.77

Margin Of Safety %

-5

Put/Call OI Ratio

0.35

EPS Next Q Diff

-1.33

EPS Last/This Y

7.86

EPS This/Next Y

0.74

Price

189.84

Target Price

242.33

Analyst Recom

Performance Q

14.52

Relative Volume

1.37

Beta

Ticker: LGND

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-13	LGND	201.23	0.46	999.99	999
2025-11-14	LGND	200.89	0.46	0.00	1000
2025-11-17	LGND	201.14	0.47	0.24	998
2025-11-18	LGND	207.39	0.46	0.00	1005
2025-11-19	LGND	206.05	0.46	1.00	1010
2025-11-20	LGND	199.07	0.46	0.00	1020
2025-11-21	LGND	199.25	0.46	0.50	1025
2025-11-24	LGND	206.71	0.32	0.00	640
2025-11-25	LGND	203.74	0.30	0.40	677
2025-11-26	LGND	206.14	0.30	999.99	681
2025-12-01	LGND	197	0.30	2.57	686
2025-12-02	LGND	195.35	0.33	0.24	709
2025-12-03	LGND	192.53	0.33	0.24	709
2025-12-04	LGND	188.38	0.32	1.00	747
2025-12-05	LGND	185.37	0.32	1.00	748
2025-12-08	LGND	184.72	0.32	0.05	749
2025-12-09	LGND	185.49	0.33	0.22	729
2025-12-10	LGND	183.99	0.33	1.00	742
2025-12-11	LGND	183.04	0.35	0.00	746
2025-12-12	LGND	189.6	0.35	0.06	742
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-13	LGND	201.27	21.1	14.5	7.63
2025-11-14	LGND	200.76	21.1	16.1	7.63
2025-11-17	LGND	201.10	21.1	16.4	7.63
2025-11-18	LGND	206.74	21.1	18.7	7.63
2025-11-19	LGND	206.05	21.1	15.9	7.63
2025-11-20	LGND	199.07	21.1	13.3	7.63
2025-11-21	LGND	199.34	21.5	16.5	7.62
2025-11-24	LGND	206.84	21.5	19.7	7.62
2025-11-25	LGND	203.52	21.5	14.8	7.62
2025-11-26	LGND	206.29	21.5	17.5	7.62
2025-12-01	LGND	197.04	21.5	13.6	7.62
2025-12-02	LGND	195.10	21.5	15.5	7.62
2025-12-03	LGND	193.03	21.5	15.4	7.62
2025-12-04	LGND	188.43	21.5	14.2	7.62
2025-12-05	LGND	184.87	21.5	14.6	7.62
2025-12-08	LGND	184.67	21.5	-	7.62
2025-12-09	LGND	185.83	21.5	16.9	7.62
2025-12-10	LGND	183.89	21.5	15.4	7.62
2025-12-11	LGND	182.97	21.5	15.8	7.62
2025-12-12	LGND	189.84	22.5	57.0	7.64
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-13	LGND	-2.85	2.78	5.77
2025-11-14	LGND	-4.90	2.78	5.77
2025-11-17	LGND	-5.07	3.15	5.77
2025-11-18	LGND	-5.07	3.15	5.77
2025-11-19	LGND	-5.07	3.15	5.77
2025-11-20	LGND	-5.07	3.15	5.77
2025-11-21	LGND	-5.07	3.15	5.77
2025-11-24	LGND	-5.07	7.26	5.77
2025-11-25	LGND	-5.07	7.26	5.77
2025-11-26	LGND	-5.07	7.26	5.47
2025-12-01	LGND	-5.07	7.14	5.47
2025-12-02	LGND	-5.07	7.14	5.47
2025-12-03	LGND	-4.88	7.14	5.47
2025-12-04	LGND	-4.97	7.14	5.47
2025-12-05	LGND	-4.97	7.14	5.47
2025-12-08	LGND	-4.97	7.07	5.47
2025-12-09	LGND	-4.99	7.07	5.47
2025-12-10	LGND	-4.99	7.07	5.77
2025-12-11	LGND	-4.99	7.07	5.77
2025-12-12	LGND	-4.99	7.07	5.77
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

[stock_market_widget type="chart" template="candlestick" assets="LGND" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

3.09

Avg. EPS Est. Current Quarter

1.56

Avg. EPS Est. Next Quarter

1.76

Insider Transactions

-4.99

Institutional Transactions

7.07

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

180.18

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

10.7

Max Drawdown 5-Year %

-65.5

Target Price

242.33

P/E

91.24

Forward P/E

23.2

PEG

1.25

P/S

14.85

P/B

3.92

P/Free Cash Flow

121.76

EPS

2.08

Average EPS Est. Cur. Y

7.64

EPS Next Y. (Est.)

8.38

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

19.34

Relative Volume

1.37

Return on Equity vs Sector %

-21.8

Return on Equity vs Industry %

-6.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”LGND” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”LGND” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”LGND” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”LGND” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”LGND” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”LGND” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”LGND” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

Ligand Pharmaceuticals Incorpor

Sector: Healthcare

Industry: Biotechnology

Employees: 68

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

stock quote shares LGND – Ligand Pharmaceuticals Incorporated Stock Price stock today

news today LGND – Ligand Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025

marketwatch LGND – Ligand Pharmaceuticals Incorporated yahoo finance google finance

stock history LGND – Ligand Pharmaceuticals Incorporated invest stock market

stock prices LGND premarket after hours

ticker LGND fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: LGND

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y